Accellacare

Make a difference - become a clinical trial participant

[Accellacare @accellacare]

We’re proud to celebrate our North London site for becoming the top enroller in a recent global study—an achievement that reflects our commitment to high‑quality, patient‑centred research. Thank you to the team for continually raising the bar. https://t.co/k1vILdklJE

[Accellacare @accellacare]

Accellacare is committed to making clinical research more accessible and efficient. In a recent UK pneumococcal vaccine study, our teams exceeded goals—achieving 153% of target ahead of schedule and contributing 61% of global randomisations across 3 sites.
https://t.co/RqNSWi7usN

[Accellacare @accellacare]

We’re committed to improving access to research for under‑recognised, hard‑to‑diagnose conditions. Our Warwickshire site demonstrated this by excelling in a challenging endometriosis study, completing enrolment 25% faster than the 6‑month target.
https://t.co/HDAcicTblz

[Accellacare @accellacare]

We’re committed to improving access to research for under‑recognised, hard‑to‑diagnose conditions. Our Warwickshire site demonstrated this by excelling in a challenging endometriosis study, completing enrolment 25% faster than the 6‑month target.
https://t.co/HDAcicTblz

[Accellacare @accellacare]

We’re proud to mark an exciting milestone in our partnership with the Brian Moran Cancer Institute. Our site achieved its first randomisation on a prostate cancer study using a novel treatment delivery system.
https://t.co/awUDF1pfzG

[Accellacare @accellacare]

March is #EndometriosisActionMonth and Accellacare is proud to stand with the millions of people affected by this often misunderstood condition.
We’re grateful to all patients, advocates, and researchers working to drive meaningful progress.

Learn more: https://t.co/awUDF1pfzG

[Accellacare @accellacare]

Our Charleston site has expanded their PI team with Dr. Alaina Payne and Dr. Jeffrey Yonce receiving their first trials as PIs in obesity and vaccine research. Their leadership helps sustain vital studies and strengthens access to care for local patients.
https://t.co/h5cKRm4MAA

[Accellacare @accellacare]

Celebrating our Rocky Mount team for 125% enrolment on a recent hyperlipidemia study. Their dedicated outreach and compassionate patient engagement makes clinical research more accessible for people in their community living with high cholesterol.
https://t.co/h5cKRm4MAA

[Accellacare @accellacare]

Happy to celebrate our Winston team for achieving 190% enrolment in a short window on a recent obesity and weight loss study.
Our dedicated team and patients made this progress possible. Together, we’re advancing research and supporting healthier futures.
https://t.co/h5cKRm4MAA

[Accellacare @accellacare]

Our Winston site has partnered with Dr. Kohl and Certus Psychiatry and Integrated Care to expand into psychiatric clinical trials. This brings more opportunities for patients to access to innovative mental-health treatments and support for vital research.
https://t.co/h5cKRm4MAA

[Accellacare @accellacare]

Our new partnership with the Brian Moran Cancer Institute at Duly Health and Care accelerates access to innovative oncology studies and specialist expertise, bringing hope to those affected by cancer.

Read more: https://t.co/AZ7BnmMlvH

[Accellacare @accellacare]

The Accellacare Cary site sets the pace for vaccine research! First patient screened in just 1.5 hours post-activation and all sentinel patients randomised in a single day.

Link: https://t.co/ECPFBH4x6G

#StudyStartUp #SiteNetwork

[Accellacare @accellacare]

Connect with our experts at the #SCRSSummit to discover how our unified approach is transforming clinical trial execution. Schedule time with our team to discuss your site’s needs and explore solutions tailored for you.

https://t.co/BulLCulKzm

[Accellacare @accellacare]

Accellacare is bringing the full power of our integrated solutions to the SCRS Global Site Solutions Summit — including our Site Network, In-Home Services, and Site Resourcing.

Contact us today to schedule a meeting with Accellacare experts.
https://t.co/nGoHD8XijV

[Accellacare @accellacare]

In just a few days, ICON will be at #DPHARM2025, 16 -17 September. Visit booth #305 to learn how we accelerate trial success and don’t miss Faith Gabel’s session on site networks.
https://t.co/hANFKDMuji

[Accellacare @accellacare]

Biomarkers are driving drug development. This expert-led report produced in conjunction with Drug Target Review explores how biomarker science is advancing trial design, accelerating clinical decisions and driving the future of precision medicine.
https://t.co/zcvbDJAN2q

[Accellacare @accellacare]

ICON will be at #DPHARM2025 this 16–17 September. Visit booth #305 to learn how our clinical, consulting, and commercial expertise drives trial efficiency and delivers better patient outcomes. Join us to transform clinical research through innovation. https://t.co/SE9sLnzmkI

[Accellacare @accellacare]

ICON is pleased to join industry leaders at #DPHARM2025 this 16 - 17 September. Connect with our experts at booth #305 and see how our clinical, consulting, and commercial solutions accelerate innovation and improve patient outcomes. https://t.co/SE9sLnzmkI

[Accellacare @accellacare]

Congratulations to Dr. Kevin Cannon, named a 2025 #HealthcareResearchAllStar by @AvantGardeHlth!
A powerhouse in clinical research and a true changemaker—this recognition is well-earned.

#ClinicalTrials #MedicalResearch #Innovation

[Accellacare @accellacare]

Accellacare PI, Dr. John Parker, worked on a newly published study in Diabetes Care.
Adults with T2D + hypercortisolism saw improved glycemic control with mifepristone treatment—a major step for targeted care.
Read more: https://t.co/JFvA0N10rG